1. Introduction {#sec1-dentistry-03-00133}
===============

Pulpo-dentinal repair dynamics via tissue-specific mechanisms has provided operative dentistry with various treatment strategies to maintain pulp tissue in a healthy and functional state, whenever the dentin-pulp complex has been compromised by caries, trauma or restorative procedures. The techniques used for the treatment of pulp exposures in primary and permanent teeth are called direct pulp capping and pulpotomies (partial or superficial pulpotomy and full or pulp chamber pulpotomy). Direct pulp capping is indicated for small and short-term pulpal exposures of permanent teeth resulting from mechanical or traumatic injury, while partial pulpotomy is indicated for large mechanical or traumatic exposures. Full pulpotomy is the treatment of choice for long-standing exposures to the oral environment. Since both techniques share common objectives, *i.e*., to minimize reversible inflammatory reactions and to protect the pulp from the effects of further bacterial, chemical, and thermo-mechanical insults, the materials used are described as one group, pulp capping materials (PCM) in the literature, despite the fact that a few of them have only been proposed for pulpotomy situations (e.g., formocresol).

Hundreds of experimental and observational studies over the last 6 decades have focused on evaluation of various vital pulp therapy (VPT) techniques and materials \[[@B1-dentistry-03-00133],[@B2-dentistry-03-00133]\]. On the other hand, numerous attempts including novel biomaterials and tissue engineering approaches with stem cells or bioactive-molecule-based applications have been designed, and their preclinical testing has been undertaken. Today it is widely accepted that the most important determinant for the long-term prognosis of vital pulp therapy is the effective control of external stimuli that can affect the underlined pulp, with the recognition that the post-operative infection is of primary importance. The present article aims to critically review the therapeutic validity of PCMs and the reliability of the criteria used in their preclinical evaluation.

1.1. Clinical Variables in Direct Pulp Capping and Pulpotomy {#sec1dot1-dentistry-03-00133}
------------------------------------------------------------

Numerous experimental and clinical studies have clearly shown that a successful outcome for vital pulp therapy is primarily dependent on the type of injury, though other variables related to the state of the dentin-pulp complex and the treatment modality have also been investigated. In general:

1.  Among various clinical variables that have been accounted as factors playing a role in the outcome of the vital pulp therapy, the most important are issues related to case selection, which remains the most important parameter for the clinical success of exposed pulp treatment \[[@B1-dentistry-03-00133]\]. It is generally accepted that prognosis of direct pulp capping or pulpotomy therapies in teeth with pulp exposures remains as one of the most problematic and unpredictable methods of dental treatment. Horsted *et al.* 1985 reported that pulp survival rates of carefully selected cases treated with calcium hydroxide as capping agent was initially high (more than 80% after 5 years), but they are declining over time \[[@B3-dentistry-03-00133]\]. Pulpal exposure due to caries shows very limited potential for pulp survival due to bacterial infection of the pulp for a substantial period of time, which compromises the defense reaction \[[@B4-dentistry-03-00133]\]. In the case selection parameter, the different treatment goals of vital pulp therapy in primary and developing permanent teeth might be critically reviewed. Dental treatment of primary teeth must satisfy different goals than treatment for mature permanent teeth, due to the limited life span of primary teeth and their possible relationship to the permanent tooth successor. Although recent advances in primary tooth biology clearly demonstrated that these teeth have also a potential for wound healing with tertiary dentin formation \[[@B5-dentistry-03-00133]\], the criteria used for evaluation of PCM have not been re-evaluated and in many cases PCM with different properties are used. Similarly, dental treatment of immature permanent teeth must satisfy different goals than treatment for mature permanent teeth, due to the central role of the pulp in the physiological continuation of root development and in further deposition of primary dentin which strengthens the root dentinal walls. Thus, preservation of pulp vitality is particularly important in the immature permanent teeth, even with very different treatment indications. The absence of toxicity in PCMs and their further ability to minimize pulp inflammation and enhance pulp healing has been recognized as an important factor in the outcome of VPT \[[@B6-dentistry-03-00133],[@B7-dentistry-03-00133],[@B8-dentistry-03-00133]\].

2.  It has been recognized that dental pulp responds to external irritation with the set of stereotypic defensive mechanisms of the connective tissues. Whenever dentin and pulp is affected by caries, a network of inflammatory reactions of pulpal cells, micro-circulation and nerves, restorative procedures and trauma directly affects the outcome of the fundamental defensive mechanisms in the dental pulp. In patho-physiological terms the most significant difference between dental pulp and other connective tissues is the low compliance environment of the dentinal walls and the relatively constant pulp tissue volume \[[@B9-dentistry-03-00133]\]. Initial vascular reactions during pulp inflammation (vasodilatation and increased vessel permeability) taking place in the rigid enclosed pulp chamber create conditions of increased hydrostatic tissue pressure. Local reflex reactions due to activation of sensory nerve fibers and subsequent release of vasoactive peptides might be beneficial to the pulp organ under low-grade tissue irritations \[[@B10-dentistry-03-00133]\]. However, under prolonged irritation, and despite the oedema-preventing mechanisms \[[@B9-dentistry-03-00133]\], dental pulp pressure can quickly suffer irreversible damage. Thus dental pulp healing does not always follow the sequence of events taking place normally in other connective tissues. Since pulp repair is strongly dependent on a number of factors, exacerbation of an initial inflammatory reaction very often leads to general tissue necrosis.

3.  It is well-known that pulpal wound healing depends largely on the extent to which infection can be avoided \[[@B2-dentistry-03-00133]\]. Control of pre-operative infection seems to be a prerequisite for the success of vital pulp therapy. Furthermore, the control of post-operative infection depends largely on the integrity of restoration and the ability of healed dentin-pulp complex to withstand the leaking oral bacteria. Thus, the nature of the healing mechanism determines the therapeutic validity of each vital pulp treatment modality and the PCM used. The role of physico-chemical and/or biological properties of PCM in the effective control of post-operative infection still remain an unknown clinical concern.

In order to explore our understanding of therapeutic validity of the PCM and its role in the successful outcome of a given treatment modality, the knowledge on the reparative potential of the treated dental pulp, the biology of tertiary dentinogenesis and regenerative dynamics of dentin-pulp complex are briefly reviewed.

1.2. Dentinogenesis in Health and Disease {#sec1dot2-dentistry-03-00133}
-----------------------------------------

Only the cells of the embryonic precursor of dental pulp, the dental papilla, possess the ability to differentiate into odontoblastic cells forming primary dentin \[[@B11-dentistry-03-00133]\]. No other population of adult mesenchymal cells has the ability to differentiate into odontoblasts and this specific ability seems to be acquired by morphogenic influences during tooth development \[[@B12-dentistry-03-00133],[@B13-dentistry-03-00133]\]. Odontoblasts physiologically form a dentin matrix during tooth development (primary dentin) and post-developmentally throughout of their lifespan (secondary dentin). Odontoblasts are further able to respond to exogenous stimuli, forming the reactionary type of tertiary dentin. After the destruction of primary odontoblasts, pulp cells which become new odontoblasts (odontoblast-like cells) form the reparative type of tertiary dentin. Tertiary dentin of both types, forming as a part of the wound healing mechanism in the pulp environment or in response to specific molecular signal, repairs the pulp-dentin complex in a specific spatial pattern \[[@B14-dentistry-03-00133],[@B15-dentistry-03-00133]\]. This seems to be in line with the critical biological validity of a modality used in VPT. The other types of mineralized matrices in the repairing pulp environment, named fibrodentin or osteodentin, might be distinguished from tertiary dentin \[[@B16-dentistry-03-00133]\]. Apparently, these products represent defensive matrices of atypical scar-like form rather than pulp-specific tissues. However, the stereotypic processes taking place in defensive mechanisms cannot be clinically controlled and their end-result cannot be predicted \[[@B17-dentistry-03-00133]\]. Atypical hard tissue barriers are characterized by their unspecific nature and their porosity due to the osteotypic appearance of the secreted matrix. Both outcomes might be recognized as potential failures of the VPT. The atypical hard tissue has no barrier effect; it is formed at the expense of the dental pulp leading to pulp obliteration, and it is not effective in protecting the pulp from leaking bacterial threats.

1.3. The Reparative and Regenerative Potential of Traumatized Dentin-Pulp Complex {#sec1dot3-dentistry-03-00133}
---------------------------------------------------------------------------------

The irritation of the traumatized dental-pulp complex due to acute physical or mechanical trauma, including the trauma of pulp exposure, usually causes reversible pulpal damage. In the absence of chronic irritation, the dental pulp can be recovered \[[@B18-dentistry-03-00133]\]. As has been already stated, contamination of the amputated pulp with oral bacteria has been widely recognized as the most critical factor for continuing pulp inflammation and necrosis \[[@B4-dentistry-03-00133]\]. Subsequently, the ability of PCM to provide an effective barrier effect able to oppose the external irritation of the pulp-dentin complex must be directly associated with its therapeutic validity. From the first introduction of pulp capping as a treatment alternative for the exposed dental pulp, the main interest has been focused on the dentinogenic potential of pulp cells and how the PCM can release morphogenetic factors from the dentin matrix \[[@B19-dentistry-03-00133]\] and/or induce cell proliferation, migration, adhesion and differentiation, *i.e*., the formation of a dentinal barrier at the exposure site. It might be noticed here that many observational and experimental studies have documented that the exposed dental pulp can survive even in the absence of dentinal barrier \[[@B1-dentistry-03-00133]\]. Taking this into consideration, the ability of dental materials to provide the necessary barrier effect through "hermetic" sealing of the exposure site has been also investigated as the basic criterion for the therapeutic validity of a given pulp treatment modality, despite the fact that many investigators stated that in this case the risk for pulp infection, inflammation and necrosis is extremely high. Of course, it is reasonable to conclude that combination of the dentino-inductive and sealing properties in one PCM should represent the ideal solution. In any case, the inductive properties seem to be among the primary requirements from the PCM.

The nature of the dentinal barrier has been progressively recognized as a further criterion in evaluating the reliability of PCM, which needs to be further specified. Most investigations have documented that whenever the basic structure of pulp periphery is destroyed, hard tissue formation takes place as a part of the wound healing mechanism. However, clinical data showed that despite the presence of hard tissue barrier, treatment failed due to a secondary pulp infection. Experimental approaches showed that hard tissue which is formed as a part of the healing process results in formation of dentinal bridges with numerous tunnels and defects. Since pulp cells express a wide spectrum of mineralized matrices, it is crucial to distinguish the various types of hard tissue barriers formed in various pathological conditions at the pulp-dentin complex \[[@B16-dentistry-03-00133]\].

The cellular events taking place after direct pulp capping treatment have been studied by using calcium hydroxide-based materials. Initially the pulpal cells proliferate and elaborate a collagenous matrix in close proximity to a firm zone of destroyed pulp due to the trauma and the high alkalinity of the capping material. Mineral salts precipitating in that necrotic zone and the newly produced collagen form the first zone of calcified matrix around the treated pulp area. Morphologically this zone is called fibrodentin, and very often it has osteotypic appearance and does not include any tissue specific cytodifferentiative event \[[@B16-dentistry-03-00133],[@B20-dentistry-03-00133]\]. If subsequent reactions lead to wound healing, the dentinogenic potential of pulpal cells can be expressed. Cells migrate toward the superficial calcified zone, attach and display the cytological characteristics of odontoblastic lineage forming a tubular mineralized matrix in a polar predentin-like pattern \[[@B7-dentistry-03-00133],[@B20-dentistry-03-00133]\]. It seems that the primitive calcified matrix plays a role in differentiation of odontoblast-like cells, and this action calls to mind the role of the basement membrane during primary odontoblast differentiation in mediating epithelial-mesenchymal interactions \[[@B11-dentistry-03-00133]\]. It offers a mechanical support for immobilization of pulpal cells, though accumulation of endogenous extracellular matrix molecules (fibronectin and TGFβ1 among others) playing a role in the terminal odontoblast-like cell differentiation has been also suggested \[[@B14-dentistry-03-00133],[@B21-dentistry-03-00133]\]. In any case, fibrodentin/osteodentin matrix formation seems to be an intermediate step during the onset of reparative dentinogenesis as a part of the wound healing process.

In conclusion, the clinical exploitation of dentinogenic potential of pulp cells represent the rational basis of evaluating biological reliability of PCM \[[@B8-dentistry-03-00133]\]. It is now a necessity to put the evaluation of PCM into a broader perspective. The therapeutic validity of a given pulp treatment strategy has to be associated with two main biological properties of the PCM: -Biocompatibility, defined as the absence of toxic effects which can interfere with the overall outcome of the inflammatory process in the pulp, and-Biological specificity, defined as the ability to signal odontoblast-like cell differentiation and reparative dentin formation instead the indirect stimulation of wound healing with hard tissue formation.

The aim of the present article is to perform a literature review on the therapeutic validity of various materials used in vital pulp therapy over the last 6 decades, as is indicated by their specific dentinogenic activity. Since the detailed pulp response to the capping materials, including both newly formed mineralized tissue and the associated formative cells characterization, requires evaluation at the light or transmission electron microscopic level, the relative histological studies were only reviewed.

2. Data Sources and Resources Selection {#sec2-dentistry-03-00133}
=======================================

This critical review is based on a comprehensive literature search using the Medline/Pubmed data base covering the period from 1949 to early 2015. The database search was performed using the keywords "pulp capping histology", "pulpotomy histology", "reparative dentin" and "osteodentin and pulp cup or pulpotomy". Eligible for inclusion in this study were scientific articles that were published in the English language, with no limitations implemented by country of origin. The relevant papers included the abstracts and full text of clinical trials (original articles) that met the eligibility criteria. Unpublished research and studies that were reported only in abstract form editorials, review articles, letters to the Editor, clinical guidelines, *in vitro* studies and case reports were not considered for inclusion.

Titles and abstracts were screened and then full texts of all potentially relevant publications were obtained and reviewed by two independent reviewers (X, Y). Full paper copies of peer-reviewed papers were acquired electronically and cross references were further screened to identify relevant studies. Both reviewers were blinded to authors, journal and results. Any disagreements on study inclusion and exclusion criteria were discussed and resolved either by consensus or by consulting a third reviewer.

Inclusion of a study was dependent on having sufficient data regarding the type of the capping material used and the unit of observation (human permanent tooth *in vivo* or animal permanent dentition; primary teeth were excluded). The searches were also confined to articles presenting either clinical/radiographic data and/or histologic/histomorphometric evaluations of the post-operatively deposited tissue related to the material tested. The post-operatively deposited matrix was named with various terms, which were categorized into three types as follows: **Unspecified matrix**, where the type of newly formed mineralized matrix was characterized as hard tissue/matrix, mineralized tissue/matrix, calcified tissue/matrix or dentin bridge.**Osteotypic matrix**, where the type of newly formed mineralized matrix was characterized as osteodentin, fibrodentin, osteotypic hard tissue/matrix, atubular dentin or reparative dentin without any indication of tubular structure, and**Dentin-like matrix**, where the type of newly formed mineralized matrix was characterized by its tubular structure and was named as reparative dentin, tertiary dentin, new dentin, dentin-like or tubular mineralized tissue/matrix, with indication of presence of elongated formative cells, or odontoblast-like cells or new odontoblasts.

Review
------

One hundred fifty two studies were included in the final evaluation. In [Table 1](#dentistry-03-00133-t001){ref-type="table"} the studies are shown with their reference data, species, capping material(s) used and the type of mineralized tissue(s) formed according to the categorization mentioned above.

dentistry-03-00133-t001_Table 1

###### 

The 152 studies which have been included in the present systematic review. Data concerning the used experimental model(s), capping material(s) and the type of newly formed mineralized tissue(s) are shown. Abbreviations: CH calcium hydroxide-based material, MTA mineral trioxide aggregates-based material, PC Portland cement-based material, BD biodentine, CP calcium phospate-based material, HA hydroxyapatite-based material, BG bioactive glass-based material, EMP enamel matrix protein-based material, FS ferric sulphate, FC formocresol, BMA bioactive molecule-based application, ZOE zinc oxide & eugenol-based material, RS glass ionomer and resin-based materials, U unspecified mineralized tissue, OSD osteotypic matrix, DL dentin-lik matrix.

  References                                                Model        Capping Material(s)   Type of Matrix
  --------------------------------------------------------- ------------ --------------------- ----------------
  Zhang *et al.* \[[@B22-dentistry-03-00133]\]              Rat          MTA, PC               DL
  Cannon *et al.* \[[@B23-dentistry-03-00133]\]             Monkey       RS, PC                U
  Swarup *et al.* \[[@B24-dentistry-03-00133]\]             Human        CP, MTA, CH           DL
  Han *et al.* \[[@B25-dentistry-03-00133]\]                Rat          MTA                   DL
  Tziafa *et al.* \[[@B26-dentistry-03-00133]\]             Pig          MTA, BD               OSD + DL
  Obeid *et al.* \[[@B27-dentistry-03-00133]\]              Dog          MTA, CP, Other        U
  Nowicka *et al.* \[[@B28-dentistry-03-00133]\]            Human        BD, MTA               OSD + DL
  Hutcheson *et al.* \[[@B29-dentistry-03-00133]\]          Human        MTA                   U
  Omar *et al.* \[[@B30-dentistry-03-00133]\]               Dog          FS, Other             U
  Sushynski *et al.* \[[@B31-dentistry-03-00133]\]          Human        FS, MTA               DL
  Nowicka *et al.* \[[@B32-dentistry-03-00133]\]            feline       RS, CH                DL
  Cardoso-Silva *et al.* \[[@B33-dentistry-03-00133]\]      Human        MTA                   U
  Fransson *et al.* \[[@B34-dentistry-03-00133]\]           Human        BMA, CH               OSD + DL
  Shahravan *et al.* \[[@B35-dentistry-03-00133]\]          Human        MTA                   U
  Zarrabi *et al.* \[[@B36-dentistry-03-00133]\]            Human        MTA, other            DL
  Shayegan *et al.* \[[@B37-dentistry-03-00133]\]           Pig          HA, CH, FC            U
  Zealand *et al.* \[[@B38-dentistry-03-00133]\]            Human        FC, MTA               U
  Zarrabi *et al.* \[[@B39-dentistry-03-00133]\]            Human        MTA, other            DL
  Parolia *et al.* \[[@B40-dentistry-03-00133]\]            Human        Other, MTA, CH        DL
  Sakai *et al.* \[[@B41-dentistry-03-00133]\]              Human        MTA, PTC              U
  Shayegan *et al.* \[[@B42-dentistry-03-00133]\]           Pig          CP, CH, MTA, PTC      U
  Accorinte *et al.* \[[@B43-dentistry-03-00133]\]          Human        MTA                   U
  Kiatwateeratana *et al.* \[[@B44-dentistry-03-00133]\]    Human        EMP, CH               DL
  Accorinte *et al.* \[[@B45-dentistry-03-00133]\]          Human        MTA, CH               U
  Accorinte *et al.* \[[@B46-dentistry-03-00133]\]          Human        MTA, CH               U
  Moretti *et al.* \[[@B47-dentistry-03-00133]\]            Human        MTA, CH, FC           U
  Sawicki *et al.* \[[@B48-dentistry-03-00133]\]            Human        MTA, CH               U
  Nair *et al.* \[[@B49-dentistry-03-00133]\]               Human        MTA or CH             U
  Lu *et al.* \[[@B50-dentistry-03-00133]\]                 Human        RS, CH                DL
  Min *et al.* \[[@B51-dentistry-03-00133]\]                Human        MTA, CH               DL
  Fernandes *et al.* \[[@B52-dentistry-03-00133]\]          Human        CH, RS                DL
  Qudeimat *et al.* \[[@B53-dentistry-03-00133]\]           Human        MTA, CH               U
  Tziafas *et al.* \[[@B54-dentistry-03-00133]\]            Dog          RS, CH, Other         U
  Elias *et al.* \[[@B55-dentistry-03-00133]\]              Human        CH, RS                DL
  Iwamoto *et al.* \[[@B56-dentistry-03-00133]\]            Human        MTA, CH               U
  Caicedo *et al.* \[[@B57-dentistry-03-00133]\]            Human        MTA                   U
  Silva *et al.* \[[@B58-dentistry-03-00133]\]              Human        RS, CH                DL
  Piva *et al.* \[[@B59-dentistry-03-00133]\]               Human        CH                    OSD + DL
  Olsson *et al.* \[[@B60-dentistry-03-00133]\]             Human        EMP, CH               U
  Markovic *et al.* \[[@B61-dentistry-03-00133]\]           Human        FC, CH                U
  Koliniotou & Tziafas. \[[@B62-dentistry-03-00133]\]       Dog          RS, CH                U
  Maroto *et al.* \[[@B63-dentistry-03-00133]\]             Human        MTA                   U
  Suzuki *et al.* \[[@B64-dentistry-03-00133]\]             Rat          RS, Other             DL
  Accorinte *et al.* \[[@B65-dentistry-03-00133]\]          Human        CH, RS                DL
  Menezes *et al.* \[[@B66-dentistry-03-00133]\]            Dog          MTA, PTC              U
  Agamy *et al.* \[[@B67-dentistry-03-00133]\]              Human        MTA, FC               DL
  Iohara *et al.* \[[@B68-dentistry-03-00133]\]             Pig          BMA                   DL
  Nakashima *et al.* \[[@B69-dentistry-03-00133]\]          Dog          BMA                   DL
  Salako *et al.* \[[@B70-dentistry-03-00133]\]             Human        BG, MTA, FS, FC       DL
  Hörsted-Bindslev *et al.* \[[@B71-dentistry-03-00133]\]   Human        RS, CH                DL
  Scarano *et al.* \[[@B72-dentistry-03-00133]\]            Human        RS, CH, other         DL
  Tziafas *et al.* \[[@B73-dentistry-03-00133]\]            Dog          MTA                   OSD + DL
  Tziafas *et al.* \[[@B74-dentistry-03-00133]\]            Dog          BMA, Other            OSD + DL
  Kitasako *et al.* \[[@B75-dentistry-03-00133]\]           Monkey       RS, CH                DL
  Murray *et al.* \[[@B76-dentistry-03-00133]\]             Monkey       CH, RS                DL
  Hafez *et al.* \[[@B77-dentistry-03-00133]\]              Monkey       RS, CH                DL
  Six *et al.* \[[@B78-dentistry-03-00133]\]                Rat          BMA, CH               OSD + DL
  Nakamura *et al.* \[[@B79-dentistry-03-00133]\]           Pig          CH, EMP               OSD + DL
  Tziafas *et al.* \[[@B80-dentistry-03-00133]\]            Dog          BMA, HA, CH, Other    OSD + DL
  Goldberg *et al.* \[[@B81-dentistry-03-00133]\]           Rat          BMA, CH               OSD + DL
  Lovschall *et al.* \[[@B82-dentistry-03-00133]\]          Rat          BMA, CH               DL
  Rutherford. \[[@B83-dentistry-03-00133]\]                 Rat          BMA                   DL
  Blanko *et al.* \[[@B84-dentistry-03-00133]\]             Human        CH                    U
  Pereira *et al.* \[[@B85-dentistry-03-00133]\]            Human        CH, RS                DL
  Decup *et al.* \[[@B86-dentistry-03-00133]\]              Rat          BMA, CH               DL
  Waterhouse *et al.* \[[@B87-dentistry-03-00133]\]         Human        FC, CH                DL
  Hayashi *et al.* \[[@B88-dentistry-03-00133]\]            Rat          CP                    OSD + DL
  Kitasako *et al.* \[[@B89-dentistry-03-00133]\]           Monkey       RS                    U
  Hebling *et al.* \[[@B90-dentistry-03-00133]\]            Human        RS, CH                U
  Tarim *et al.* \[[@B91-dentistry-03-00133]\]              Monkey       RS, ZOE, CH           U
  Tziafas *et al.* \[[@B92-dentistry-03-00133]\]            Dog          BMA                   OSD + DL
  Tziafas & Papadimitriou. \[[@B93-dentistry-03-00133]\]    Dog          BMA                   OSD + DL
  Jepsen *et al.* \[[@B94-dentistry-03-00133]\]             Pig          BMA, CH               OSD + DL
  Ford *et al.* \[[@B95-dentistry-03-00133]\]               Monkey       MTA, CH               U
  Tziafas *et al.* \[[@B96-dentistry-03-00133]\]            Dog          CH                    OSD + DL
  Yoshiba *et al.* \[[@B97-dentistry-03-00133]\]            Human        CH                    OSD + DL
  Tziafas *et al.* \[[@B98-dentistry-03-00133]\]            Dog          BMA                   OSD + DL
  Sasaki & Kawamata-Kido. \[[@B99-dentistry-03-00133]\]     Rat          HA, CH                OSD + DL
  Oguntebi *et al.* \[[@B100-dentistry-03-00133]\]          Pig          BG, CH, BMA, Other    U
  Yoshimine *et al.* \[[@B101-dentistry-03-00133]\]         Rat          CP, CH                U
  Yoshiba *et al.* \[[@B102-dentistry-03-00133]\]           Monkey       CP, CH, Other         U
  Tziafas *et al.* \[[@B103-dentistry-03-00133]\]           Dog          BMA, CH               OSD + DL
  Nakashima. \[[@B104-dentistry-03-00133]\]                 Dog          BMA                   OSD + DL
  Tziafas *et al.* \[[@B105-dentistry-03-00133]\]           Dog          BMA                   OSD + DL
  Oguntebi *et al.* \[[@B106-dentistry-03-00133]\]          Pig          BG, BMA, CH           DL
  Imai *et al.* \[[@B107-dentistry-03-00133]\]              Rat          CP, CH                OSD + DL
  Lianjia *et al.* \[[@B108-dentistry-03-00133]\]           Bovine       BMA                   OSD + DL
  Rutherford *et al.* \[[@B109-dentistry-03-00133]\]        Monkey       BMA, CH               OSD + DL
  Robson & Katz. \[[@B110-dentistry-03-00133]\]             Rat          BMA                   OSD + DL
  Inoue & Shimono. \[[@B111-dentistry-03-00133]\]           Rat          RS                    U
  Tziafas *et al.* \[[@B112-dentistry-03-00133]\]           Dog          BMA                   OSD + DL
  Tziafas *et al.* \[[@B113-dentistry-03-00133]\]           Dog          BMA                   OSD + DL
  Jaber *et al.* \[[@B114-dentistry-03-00133]\]             Rat          HA, CH                DL
  Furusawa *et al.* \[[@B115-dentistry-03-00133]\]          Human        CP                    U
  Mjor *et al.* \[[@B116-dentistry-03-00133]\]              Monkey       CH                    DL
  Fitzgerald & Heys. \[[@B117-dentistry-03-00133]\]         Human        CH                    U
  van Mullem. \[[@B118-dentistry-03-00133]\]                Pig          Untreated             OSD + DL
  Nakashima. \[[@B119-dentistry-03-00133]\]                 Dog          BMA                   OSD + DL
  Smith *et al.* \[[@B120-dentistry-03-00133]\]             Ferret       BMA                   OSD + DL
  Fitzgerald *et al.* \[[@B121-dentistry-03-00133]\]        Monkey       CH                    U
  Ikami *et al.* \[[@B122-dentistry-03-00133]\]             Monkey       CP                    U
  Tziafas & Kolokuris. \[[@B123-dentistry-03-00133]\]       Dog          BMA                   OSD + DL
  Heys *et al.* \[[@B124-dentistry-03-00133]\]              Monkey       CH, Other             U
  Nakashima. \[[@B125-dentistry-03-00133]\]                 Dog          BMA                   OSD + DL
  Tziafas. \[[@B126-dentistry-03-00133]\]                   Dog          CH, other             U
  Oguntebi *et al.* \[[@B127-dentistry-03-00133]\]          Monkey       BMA, ZOE              U
  Tziafas & Molyvdas. \[[@B128-dentistry-03-00133]\]        Dog          CH                    OSD + DL
  Jean *et al.* \[[@B129-dentistry-03-00133]\]              Pig          CP, HA, CH            OSD + DL
  Cvek *et al.* \[[@B130-dentistry-03-00133]\]              Monkey       CH, other             OSD + DL
  Cox *et al.* \[[@B131-dentistry-03-00133]\]               Monkey       RS, others            DL
  Heide & Kerekes. \[[@B132-dentistry-03-00133]\]           Monkey       CH                    U
  Heide & Kerekes. \[[@B133-dentistry-03-00133]\]           Monkey       CH                    U
  Cox & Bergenholtz. \[[@B134-dentistry-03-00133]\]         Monkey       CH                    OSD + DL
  Schroder U. \[[@B20-dentistry-03-00133]\]                 Human        CH                    OSD + DL
  Cox *et al.* \[[@B135-dentistry-03-00133]\]               Monkey       CH                    U
  Fuks *et al.* \[[@B136-dentistry-03-00133]\]              Monkey       BMA                   OSD + DL
  Goldberg *et al.* \[[@B137-dentistry-03-00133]\]          Human        CH, CP                U
  Heide & Mjor. \[[@B138-dentistry-03-00133]\]              Human        Others                U
  Garcia-Godoy *et al.* \[[@B139-dentistry-03-00133]\]      Dog          FC                    U
  Cox *et al.* \[[@B140-dentistry-03-00133]\]               Monkey       CH                    U
  Heys *et al.* \[[@B141-dentistry-03-00133]\]              Monkey       CH, ZOE, CP, Others   DL
  Inoue *et al.* \[[@B142-dentistry-03-00133]\]             Rat          BMA                   U
  Horsted *et al.* \[[@B143-dentistry-03-00133]\]           Monkey       CH, Other             U
  Dick & Carmichael. \[[@B144-dentistry-03-00133]\]         Dog          BMA                   U
  Fitzgerald. \[[@B145-dentistry-03-00133]\]                Monkey       CH                    OSD + DL
  McWalter *et al.* \[[@B146-dentistry-03-00133]\]          Monkey       CH, Others            U
  Heller *et al.* \[[@B147-dentistry-03-00133]\]            Monkey       CP, CH                U
  Cotton. \[[@B148-dentistry-03-00133]\]                    Rat          CH, ZnOE              U
  Cotton. \[[@B149-dentistry-03-00133]\]                    Rat          CH                    U
  Tronstad. \[[@B150-dentistry-03-00133]\]                  Monkey       CH                    U
  Schroder & Sundstrom. \[[@B151-dentistry-03-00133]\]      Human        CH                    OSD + DL
  Schroder. \[[@B152-dentistry-03-00133]\]                  Human        CH                    OSD + DL
  Sella *et al.* \[[@B153-dentistry-03-00133]\]             Rat          CH                    U
  Mc Walter *et al.* \[[@B154-dentistry-03-00133]\]         Monkey       CH, Other             U
  Stanley & Lundy. \[[@B155-dentistry-03-00133]\]           Human        CH                    U
  Anneroth & Bang. \[[@B156-dentistry-03-00133]\]           Monkey       BMA                   U
  Tronstad & Mjor. \[[@B157-dentistry-03-00133]\]           Monkey       CH, ZOE               U
  Ulmansky *et al.* \[[@B158-dentistry-03-00133]\]          Human        CH                    U
  Schroder & Granath. \[[@B159-dentistry-03-00133]\]        Human        CH                    OSD + DL
  Berkman *et al.* \[[@B160-dentistry-03-00133]\]           Human        Others                U
  Schroder & Granath. \[[@B161-dentistry-03-00133]\]        Human        CH                    OSD + DL
  Ulmansky *et al.* \[[@B162-dentistry-03-00133]\]          Human        CH, other             DL
  Langer *et al.* \[[@B163-dentistry-03-00133]\]            Human        CH, ZOE               U
  Bhaskar *et al.* \[[@B164-dentistry-03-00133]\]           Rat          CH, other             U
  Kakehashi *et al.* \[[@B165-dentistry-03-00133]\]         Rat          Other                 DL
  Kakehashi *et al.* \[[@B18-dentistry-03-00133]\]          Rats         Untreated             U
  Pisanti & Sciaky. \[[@B166-dentistry-03-00133]\]          Dog          CH                    U
  Sciaky & Pisanti. \[[@B167-dentistry-03-00133]\]          Dog          CH                    U
  Kalnins & Frisbie. \[[@B168-dentistry-03-00133]\]         Human        Untreated             U
  Berman & Massler. \[[@B169-dentistry-03-00133]\]          Rat          CH, ZOE               U
  Nyborg. \[[@B170-dentistry-03-00133]\]                    Human, Dog   CH                    U
  Glass & Zander. \[[@B18-dentistry-03-00133]\]             Human        CH, ZOE, other        U

3. Data Analysis {#sec3-dentistry-03-00133}
================

Experimental model: Sixty studies (39.2%) were performed on human teeth, while the following species were also used for the animal experimentation: non-human primates in 31 studies (20.2%), non-primates in 39 studies (25.4%), including dogs, pigs, felines, and bovine species, and rodents in 25 studies (16.3%), including rats, mice and ferrets.

Capping material: Ninety-three studies (60.7%) used calcium-hydroxide-based materials as testing or control material. After introduction of MTA as a capping material in 1996, 35 studies (22.8%) used tricalcium-silicate-based materials. It is noteworthy that of the 54 studies published after 2003, MTA was used in 31 studies (57.4%). In 82 studies, other dental materials have been used: in 20 resin-based materials (13%), in 18 calcium phosphate-based materials (11.7%), in 8 zinc oxide eugenol-based materials (5.2%) and in 39 studies (25.5%) other materials (ferric, sulfate, formaldeyde, amalgam, *etc.*) were applied. In thirty-seven studies (24.2%), bioactive-molecule-based applications including growth factors, bone morphogenetic proteins, enamel proteins, *etc.*, were used.

Regarding the form and structure of the mineralized bridge, the type of hard tissue bridge was characterized as follows: In 74 (48.3%) studies, only the presence of a mineralized bridge was reported. The type of mineralized matrix was not adequately described and characterized as hard, mineralized or calcified tissue or dentin bridge.In 33 (21.6%) studies, the form of the mineralized bridge was evaluated according to morphological or molecular characterization of the newly formed matrix. The type of mineralized matrix was categorized as a dentin-like matrix, but without any information on whether this type of mineralized matrix characterized the whole structure of the mineralized bridge.In 46 (30.1%) studies, the form of the mineralized bridge was evaluated according to morphological or molecular characterization of the newly formed matrix, and two types of mineralized matrix have been reported. A firm zone of a mineralized matrix, which was categorized as an osteotypic mineralized matrix, was always followed by the mineralized matrix categorized as dentin-like matrix.

The data per decade concerning the experimental model, capping materials used and type of hard tissue bridge are shown in [Figure 1](#dentistry-03-00133-f001){ref-type="fig"}, [Figure 2](#dentistry-03-00133-f002){ref-type="fig"} and [Figure 3](#dentistry-03-00133-f003){ref-type="fig"}, respectively.

![Number of experimental pulp capping histological studies (y-axis) performed in different experimental models per decade.](dentistry-03-00133-g001){#dentistry-03-00133-f001}

![Number of experimental pulp capping histological studies (y-axis) performed by using different capping materials per decade. CH calcium hydroxide-based materials, CS calcium silicate-based materials, CP calcium phosphate-based materials, BMA bioactive molecule-based applications, RS resin-based materials.](dentistry-03-00133-g002){#dentistry-03-00133-f002}

![Number of experimental pulp capping histological studies (y-axis) with different types of post-operatively formed hard tissue, as has been previously described, per decade.](dentistry-03-00133-g003){#dentistry-03-00133-f003}

4. Conclusions {#sec4-dentistry-03-00133}
==============

It is well-accepted that both the presence and (especially) the quality of hard tissue barrier are important prognostic factors for the success of a pulp capping treatment \[[@B8-dentistry-03-00133]\]. Thus, the ultimate goal of the direct pulp capping procedure and the optimal end result of an ideal PCM in the exposed pulp might be the complete reconstitution of the anatomy of pulp periphery. Since primary dentin cannot be formed post-developmentally, the differentiation of odontoblast-like cells forming reparative dentin in a predentin-like pattern is an essential biological pre-requirement for the complete restoration of dentin-pulp complex integrity, the only predictable way to achieve the successful outcome of vital pulp therapy. Differentiation of odontoblast-like cells takes place as a part of the wound healing mechanism, or as an effect of specific signaling molecules on pulp cells. Traditional pulp capping materials stimulate or enhance the wound healing mechanism, forming a heterogeneous hard tissue bridge composed of osteodentin-fibrodentin and reparative dentin. Several experimental attempts showed that the application of exogenous signaling molecules offers opportunities for the development of new therapies. Furthermore, the presence of a cocktail of growth factors in the dentin extracellular matrix provides a tool for an endogenous signaling mechanism to modulate cellular events taking place during tertiary dentinogenesis. The ability of biomaterials to release bioactive molecules from the dentin has been documented by robust studies, providing a basis for new significant tasks in developing novel therapeutic approaches in the near future.

Addressing delivery matters need to be considered before their introduction in clinical practice. In the shorter term, the group of traditional PCMs remains as the only therapeutic possibility for effective hard tissue bridge formation at the exposure site. The ability of traditionally used PCMs to stimulate the hard tissue bridge has been documented in experimental histological pulp capping studies by using different assessment criteria. It must be assumed that the absence of uniform criteria is the reason for the fact that our knowledge on the specificity of PCMs to induce dentinogenic events is still very limited. Thus, further data are required to fully understand how the wound healing mechanism after application of a PCM could be designed as a time- and space-limited process to provide the optimal end result, avoiding incomplete restoration of pulp periphery or uncontrolled pulp obliteration.

Data from the present systematic review have shown that only 30.2% of the 152 experimental histological pulp capping studies described the heterogenic nature of the hard tissue bridge formation, while the 48.2% and 21.6% of the studies reported an homogenous hard tissue bridge characterized as hard, mineralized or calcified tissue and dentin bridge or dentin-like matrix, but without any additional information on its structural characteristics, respectively. It seems to be quite disappointing that there is a declining percentage of studies using specific criteria to characterize the hard tissue bridge over the last 30 years. As can be seen in [Figure 3](#dentistry-03-00133-f003){ref-type="fig"}, 52.6%, 32.4% and 10.2% of the studies used specific characterization of the type of post-operatively formed hard tissue in the periods 1986--1995, 1996--2005 and 2006--2015, respectively. In the present study, our knowledge about the nature of pulp wound healing mechanisms is highlighted as a critical requirement in the selection of the appropriate vital pulp therapy procedure and capping materials in various clinical conditions. Additionally, it is suggested that an international consensus must be reached on selected mandatory criteria to optimally characterize the reparative events in vital pulp therapy.
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